Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Immune changes could signal inflammatory bowel disease up to 10 years before diagnosis (opens in a new tab)

medicalxpress.com · 2026-10-18

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

One key claim is not backed by the study. 4 other points were not covered by the paper.

  • 2 supported
  • 1 overstated
  • 1 not supported
  • 4 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

Two claims go beyond the study. One overstates it and one isn't supported at all. Four claims the study doesn't address.

  • 2 supported
  • 1 overstated
  • 1 not supported
  • 4 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

8 claims in this story

Showing all 8 claimsChoose a verdict to focus the list.

Claim 1 of 8Not supportedCompared with healthy controls, antibody diversity was significantly lower in people who later developed Crohn's disease or ulcerative colitis, with distinct antibody responses evident up to 10 years before diagnosis.View evidenceHide evidence

As statedup to 10 years before diagnosis

Why this verdict

The profile does not support the claim that antibody diversity was significantly lower in future Crohn’s disease or ulcerative colitis cases. Instead, the abstract-level profile reports increased antibody-repertoire variability up to about 4 years prediagnosis, plus specific differential antibody signatures. The story’s lead claim therefore conflicts with, or at least is not supported by, the supplied paper profile.

1

Study evidence

Antibody-repertoire variability was increased up to ~4 years before diagnosis in individuals who later developed Crohn's disease and ulcerative colitis.

“We applied PhIP-Seq to profile antibody responses in 2000 longitudinal serum samples from 200 individuals who developed Crohn's disease (CD), 200 who developed ulcerative colitis (UC) and 100 matched healthy controls”
Claim 2 of 8OverstatedIn ulcerative colitis, rising antibody responses against herpesviruses and autoantigens were accompanied by reduced reactivity to encapsulated pathogens.View evidenceHide evidence

Why this verdict

The profile supports a pre-ulcerative colitis combined antimicrobial, antiviral, and autoantibody signature, and separately reports declining responses to encapsulated bacteria in pre-IBD. But the abstract-level profile does not specifically establish rising herpesvirus responses in UC or clearly assign reduced encapsulated-pathogen reactivity specifically to UC. The story states a more specific directional UC pattern than the supplied profile verifies.

1

Study evidence

Pre-UC sera displayed a combined antimicrobial, antiviral, and autoantibody signature detectable up to 10 years before diagnosis; the autoantibody component included antibodies against the MAP kinase-activating death domain protein.

“Pre-UC was characterised by combined antimicrobial, antiviral and autoantibody signatures, including antibodies against the MAP kinase-activating death domain protein.”
2

Study evidence

Antibody responses to encapsulated bacteria (examples given: Streptococcus pneumoniae, Haemophilus, Neisseria) showed a progressive decline toward diagnosis in individuals who later developed IBD.

“In contrast, responses to encapsulated bacteria (eg, Streptococcus pneumoniae, Haemophilus, Neisseria) progressively declined towards diagnosis.”
Claim 3 of 8Not coveredResearchers analyzed 2,000 serum samples from 500 individuals, including 200 who developed Crohn's disease, 200 who developed ulcerative colitis, and 100 age- and sex-matched healthy controls, with samples taken at diagnosis and about two, four, and 10 years beforehand.View evidenceHide evidence

As stated2,000 serum samples; 500 individuals; 200 CD; 200 UC; 100 controls; up to 10 years prior

Why this verdict

The abstract-level profile supports the sample counts: 2,000 serum samples from 200 future Crohn’s disease cases, 200 future ulcerative colitis cases, and 100 matched controls, collected up to 10 years before diagnosis. However, the specific schedule stated by the story—samples taken at diagnosis and about two, four, and 10 years beforehand—is not available in the abstract-level profile.

1

Study evidence

Antibody-repertoire variability was increased up to ~4 years before diagnosis in individuals who later developed Crohn's disease and ulcerative colitis.

“We applied PhIP-Seq to profile antibody responses in 2000 longitudinal serum samples from 200 individuals who developed Crohn's disease (CD), 200 who developed ulcerative colitis (UC) and 100 matched healthy controls”
Claim 4 of 8Not coveredWhen these early antibody signatures were combined in machine-learning models, they discriminated future Crohn's disease or ulcerative colitis from healthy controls up to 10 years before diagnosis, with AUC values of 0.90 and 0.84, respectively; they also differentiated complicated from noncomplicated Crohn's disease with an AUC of 0.85.View evidenceHide evidence

As statedAUC 0.90, 0.84, and 0.85

Why this verdict

The supplied abstract-level profile does not report machine-learning models, AUC values, or discrimination of future Crohn’s disease, ulcerative colitis, or complicated Crohn’s disease. It reports antibody signatures and trajectories, but model performance metrics are not verifiable from the supplied abstract-depth evidence.

1

Study evidence

Antibody-repertoire variability was increased up to ~4 years before diagnosis in individuals who later developed Crohn's disease and ulcerative colitis.

“We applied PhIP-Seq to profile antibody responses in 2000 longitudinal serum samples from 200 individuals who developed Crohn's disease (CD), 200 who developed ulcerative colitis (UC) and 100 matched healthy controls”
2

Study evidence

Herpesvirus-directed antibody responses, notably Epstein–Barr virus (EBV)-directed antibodies, were elevated in individuals who later developed Crohn’s disease, detectable up to 10 years before diagnosis and especially prominent in those who later developed complicated or ileal disease.

“Differential analyses revealed elevated herpesvirus-directed responses (notably Epstein-Barr virus) and anti-flagellin antibodies up to 10 years prediagnosis in CD, particularly in individuals who later developed complicated or ileal disease.”
Claim 5 of 8Not coveredThe authors say the findings are an important proof of principle but need validation in independent, more diverse, prospectively followed populations before they can be translated into a clinical screening test.View evidenceHide evidence

Why this verdict

The cautionary framing is broadly consistent with profile limitations about generalisability, assay performance, and lack of detailed validation information. However, the specific author characterization as an 'important proof of principle' and the stated need for independent, more diverse, prospectively followed populations before clinical screening use are not contained in the supplied abstract-level paper profile.

Claim 6 of 8Not coveredThe lead author said the early antibody patterns may help support earlier risk detection, distinguish disease subtypes, and identify patients who could benefit from more intensive therapy earlier.View evidenceHide evidence

Why this verdict

The profile supports only general early-detection and phenotype-relevant research implications at abstract level. It does not contain the lead-author quote, nor does it verify the broader translational claims about identifying patients who may benefit from more intensive therapy earlier. Those claims may come from reporting outside the abstract, but they are not verifiable from the supplied profile.

Claim 7 of 8SupportedA large-scale study, presented at UEG Week 2026, identified distinct antibody patterns up to 10 years before the diagnosis of inflammatory bowel disease (IBD).View evidenceHide evidence

As statedup to 10 years before diagnosis

Why this verdict

The abstract-level profile supports a longitudinal prediagnostic IBD serology study using PhIP-Seq, with samples collected up to 10 years before diagnosis and disease-specific antibody signatures reported for future Crohn’s disease and ulcerative colitis. The headline framing is associational and does not overstate causality.

1

Study evidence

Antibody-repertoire variability was increased up to ~4 years before diagnosis in individuals who later developed Crohn's disease and ulcerative colitis.

“We applied PhIP-Seq to profile antibody responses in 2000 longitudinal serum samples from 200 individuals who developed Crohn's disease (CD), 200 who developed ulcerative colitis (UC) and 100 matched healthy controls”
2

Study evidence

Herpesvirus-directed antibody responses, notably Epstein–Barr virus (EBV)-directed antibodies, were elevated in individuals who later developed Crohn’s disease, detectable up to 10 years before diagnosis and especially prominent in those who later developed complicated or ileal disease.

“Differential analyses revealed elevated herpesvirus-directed responses (notably Epstein-Barr virus) and anti-flagellin antibodies up to 10 years prediagnosis in CD, particularly in individuals who later developed complicated or ileal disease.”
Claim 8 of 8SupportedIn Crohn's disease, elevated responses against herpesviruses and anti-flagellin antibodies were observed, especially in people who later developed complicated or ileal disease, while responses to encapsulated bacteria declined toward diagnosis.View evidenceHide evidence

As statedtoward diagnosis; up to 10 years before diagnosis

Why this verdict

The abstract-level profile supports elevated herpesvirus-directed responses, notably EBV, and anti-flagellin antibodies in pre-Crohn’s disease samples up to 10 years before diagnosis, especially among individuals who later developed complicated or ileal disease. It also supports progressive decline in responses to encapsulated bacteria toward diagnosis.

1

Study evidence

Herpesvirus-directed antibody responses, notably Epstein–Barr virus (EBV)-directed antibodies, were elevated in individuals who later developed Crohn’s disease, detectable up to 10 years before diagnosis and especially prominent in those who later developed complicated or ileal disease.

“Differential analyses revealed elevated herpesvirus-directed responses (notably Epstein-Barr virus) and anti-flagellin antibodies up to 10 years prediagnosis in CD, particularly in individuals who later developed complicated or ileal disease.”
2

Study evidence

Antibody responses to encapsulated bacteria (examples given: Streptococcus pneumoniae, Haemophilus, Neisseria) showed a progressive decline toward diagnosis in individuals who later developed IBD.

“In contrast, responses to encapsulated bacteria (eg, Streptococcus pneumoniae, Haemophilus, Neisseria) progressively declined towards diagnosis.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The paper profile reports increased antibody-repertoire variability up to about 4 years before diagnosis in future Crohn’s disease and ulcerative colitis, not lower antibody diversity up to 10 years.

    This is a material mismatch. The story says antibody diversity was significantly lower, whereas the supplied profile states that repertoire variability was increased up to approximately 4 years prediagnosis.

    From observational longitudinal cohort serology (PhIP-Seq); Longitudinal observational serological profiling (PhIP-Seq)

7 things the story did carry across
  • The study is an observational longitudinal PhIP-Seq serology analysis of archived prediagnostic samples from a US military cohort: 200 future Crohn’s disease cases, 200 future ulcerative colitis cases, 100 matched controls, and 2,000 samples collected up to 10 years before diagnosis.
  • Crohn’s disease prediagnostic signatures include elevated herpesvirus/EBV-directed and anti-flagellin antibody responses up to 10 years before diagnosis, particularly in later complicated or ileal disease.
  • Prediagnostic ulcerative colitis is described in the profile as a combined antimicrobial, antiviral, and autoantibody signature, including antibodies against MAP kinase-activating death domain protein.
  • Responses to encapsulated bacteria such as Streptococcus pneumoniae, Haemophilus, and Neisseria progressively declined toward IBD diagnosis.
  • The evidence is observational and does not establish causality.
  • Generalisability is uncertain because the cohort is a US military tri-service population, and validation in other populations is not established in the abstract-level profile.
  • Assay performance, reproducibility, affordability, and clinical-screening utility are not established by the abstract-level profile.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoCharacterise longitudinal prediagnostic serum antibody repertoires up to 10 years before IBD onset using PhIP-Seq in a US military cohort, and test whether repertoire variability and specific signatures change during the prodrome.observational longitudinal cohort serology (PhIP-Seq)Expand

In plain English

Observational longitudinal serology study applying PhIP-Seq to archived prediagnostic sera from a US military cohort (200 future CD, 200 future UC, 100 matched controls; 2000 samples total) collected up to 10 years before clinical IBD diagnosis to characterise antibody-repertoire trajectories and disease-specific serological signatures in the prodromal period.

Key findings

  • Antibody-repertoire variability was increased up to ~4 years before diagnosis in individuals who later developed Crohn's disease and ulcerative colitis.
  • Elevated herpesvirus-directed antibody responses, notably against Epstein–Barr virus, were detectable up to 10 years before diagnosis in individuals who later developed Crohn's disease.
“We applied PhIP-Seq to profile antibody responses in 2000 longitudinal serum samples from 200 individuals who developed Crohn's disease (CD), 200 who developed ulcerative colitis (UC) and 100 matched healthy controls”
What this piece can’t prove
  • Observational design: reported associations and temporal trajectories do not establish causality.

3 further details could not be confirmed from the summary.

2human in vivoIdentify Crohn’s disease–specific prediagnostic serological signatures (eg, herpesvirus/EBV-directed responses, anti-flagellin antibodies), and relate these signatures to later CD phenotype (eg, complicated or ileal disease).Longitudinal observational serological profiling (PhIP-Seq)Expand

In plain English

Within a longitudinal PhIP-Seq serology analysis of archived prediagnostic sera (up to 10 years before diagnosis) from a US military cohort, Crohn’s disease (pre-CD) shows disease-specific serological signatures: elevated herpesvirus-directed (notably Epstein–Barr virus) and anti-flagellin antibody responses detectable up to 10 years before diagnosis, with these signals particularly pronounced in participants who later developed complicated or ileal CD. Antibody-repertoire variability increased up to ~4 years before diagnosis in pre-CD, and responses to some encapsulated bacteria declined toward diagnosis.

Key findings

  • Herpesvirus-directed antibody responses, notably Epstein–Barr virus (EBV)-directed antibodies, were elevated in individuals who later developed Crohn’s disease, detectable up to 10 years before diagnosis and especially prominent in those who later developed complicated or ileal disease.
  • Anti-flagellin antibodies were elevated in prediagnostic sera of future CD cases up to 10 years before diagnosis, with stronger signals in individuals who subsequently developed complicated or ileal CD.
“Differential analyses revealed elevated herpesvirus-directed responses (notably Epstein-Barr virus) and anti-flagellin antibodies up to 10 years prediagnosis in CD, particularly in individuals who later developed complicated or ileal disease.”
What this piece can’t prove
  • Abstract lacks effect sizes, confidence intervals, p-values, and detailed subgroup sample counts needed to assess robustness and clinical relevance of reported associations.

4 further details could not be confirmed from the summary.

3human in vivoIdentify ulcerative colitis–specific prediagnostic serological signatures (combined antimicrobial/antiviral/autoantibody patterns, including MAP kinase-activating death domain protein antibodies).PhIP-Seq longitudinal serological cohort profilingExpand

In plain English

In a longitudinal PhIP-Seq serology study of archived prediagnostic sera from the US military cohort, individuals who later developed ulcerative colitis exhibited a combined antimicrobial, antiviral and autoantibody serological signature detectable prior to diagnosis; the abstract names antibodies against the MAP kinase-activating death domain protein as an example of the autoantibody component.

Key findings

  • Pre-UC sera displayed a combined antimicrobial, antiviral, and autoantibody signature detectable up to 10 years before diagnosis; the autoantibody component included antibodies against the MAP kinase-activating death domain protein.
“Pre-UC was characterised by combined antimicrobial, antiviral and autoantibody signatures, including antibodies against the MAP kinase-activating death domain protein.”
What this piece can’t prove
  • Summary is based on abstract-only information; full paper needed for statistical details, antigen lists, and reproducibility measures.

2 further details could not be confirmed from the summary.

4human in vivoDescribe progressive loss/decline of antibody responses to encapsulated bacteria (eg, S. pneumoniae, Haemophilus, Neisseria) toward diagnosis in individuals who develop IBD.longitudinal serological profiling (PhIP-Seq) in archived human cohortExpand

In plain English

Longitudinal serological profiling using PhIP-Seq of archived prediagnostic sera identified a progressive decline in antibody responses directed against encapsulated bacteria (examples cited: Streptococcus pneumoniae, Haemophilus, Neisseria) as individuals approached an IBD diagnosis. This trajectory was reported across pre-IBD individuals in the cohort and contrasted with other antibody trajectories (for example, increasing antiviral or anti-flagellin responses).

Key findings

  • Antibody responses to encapsulated bacteria (examples given: Streptococcus pneumoniae, Haemophilus, Neisseria) showed a progressive decline toward diagnosis in individuals who later developed IBD.
“In contrast, responses to encapsulated bacteria (eg, Streptococcus pneumoniae, Haemophilus, Neisseria) progressively declined towards diagnosis.”
What this piece can’t prove
  • Aggregation/grouping choices for encapsulated-bacteria targets and their impact on the result are not described.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

Crohnʼs disease patients with normal serology antibody assay values are still at risk of significant complications

Inflammatory Bowel Diseases · 2011 · Crossref

Source (opens in a new tab)
Candidate

A risk of difficult to treat disease in ulcerative colitis patients exists even with normal serology antibody assay values

Inflammatory Bowel Diseases · 2011 · Crossref

Source (opens in a new tab)
Candidate

High serology antibody assay values may predict for increased likelihood of disease related complications in ulcerative colitis patients and a need for more aggressive therapeutic management

Inflammatory Bowel Diseases · 2011 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.